Grace Therapeutics, Inc. (GRCE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Grace Therapeutics, Inc. (GRCE) has a cash flow conversion efficiency ratio of -0.034x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.22 Million) by net assets ($64.89 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Grace Therapeutics, Inc. market capitalisation for the company's overall valuation and market capitalisation.
Grace Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2010–2025)
This chart illustrates how Grace Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Grace Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Grace Therapeutics, Inc. ranked by their cash flow conversion efficiency. Explore Grace Therapeutics, Inc. (GRCE) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ferroamp Elektronik AB
ST:FERRO
|
-0.003x |
|
Tocvan Ventures Corp
F:TV3
|
-0.046x |
|
MedMira Inc
V:MIR
|
0.006x |
|
Big 5 Sporting Goods Corporation
NASDAQ:BGFV
|
-0.258x |
|
Soktas Tekstil Sanayi ve Ticaret AS
IS:SKTAS
|
0.124x |
|
Binh Duong Trade and Development JSC
VN:TDC
|
0.212x |
|
Elgi Rubber Company Limited
NSE:ELGIRUBCO
|
-0.203x |
|
WIIK Public Company Limited
BK:WIIK
|
0.009x |
Annual Cash Flow Conversion Efficiency for Grace Therapeutics, Inc. (2010–2025)
The table below shows the annual cash flow conversion efficiency of Grace Therapeutics, Inc. from 2010 to 2025. View GRCE share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $66.61 Million | $-14.90 Million | -0.224x | -12.02% |
| 2024-03-31 | $61.74 Million | $-12.33 Million | -0.200x | +14.70% |
| 2023-03-31 | $67.95 Million | $-15.91 Million | -0.234x | -47.11% |
| 2022-03-31 | $108.27 Million | $-17.23 Million | -0.159x | +38.13% |
| 2021-03-31 | $55.66 Million | $-14.32 Million | -0.257x | +85.43% |
| 2020-03-31 | $12.99 Million | $-22.95 Million | -1.766x | +21.30% |
| 2019-03-31 | $11.04 Million | $-24.79 Million | -2.244x | -47.43% |
| 2018-03-31 | $6.37 Million | $-9.69 Million | -1.522x | -530.30% |
| 2016-03-31 | $20.09 Million | $-4.85 Million | -0.242x | -11.49% |
| 2015-03-31 | $26.56 Million | $-5.75 Million | -0.217x | -5.95% |
| 2014-03-31 | $29.91 Million | $-6.12 Million | -0.204x | +22.00% |
| 2013-03-31 | $9.50 Million | $-2.49 Million | -0.262x | +32.45% |
| 2012-03-31 | $14.55 Million | $-5.65 Million | -0.388x | -18.23% |
| 2011-03-31 | $5.83 Million | $-1.91 Million | -0.328x | +30.67% |
| 2010-03-31 | $4.02 Million | $-1.90 Million | -0.473x | -- |
About Grace Therapeutics, Inc.
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a top… Read more